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Abstract: Cyclopiazonic acid (α-cyclopiazonic acid, α-CPA) is an indole-hydrindane-tetramic
acid neurotoxin produced by various fungal species, including the notorious food and feed
contaminant Aspergillus flavus. Despite its discovery in A. flavus cultures approximately 40 years
ago, its contribution to the A. flavus mycotoxin burden is consistently minimized by our focus
on the more potent carcinogenic aflatoxins also produced by this fungus. Here, we report the
screening and identification of several CPA-type alkaloids not previously found in A. flavus cultures.
Our identifications of these CPA-type alkaloids are based on a dereplication strategy involving
accurate mass high resolution mass spectrometry data and a careful study of the α-CPA fragmentation
pattern. In total, 22 CPA-type alkaloids were identified in extracts from the A. flavus strains examined.
Of these metabolites, 13 have been previously reported in other fungi, though this is the first
report of their existence in A. flavus. Two of our metabolite discoveries, 11,12-dehydro α-CPA and
3-hydroxy-2-oxo CPA, have never been reported for any organism. The conspicuous presence of
CPA and its numerous derivatives in A. flavus cultures raises concerns about the long-term and
cumulative toxicological effects of these fungal secondary metabolites and their contributions to the
entire A. flavus mycotoxin problem.
Keywords: cyclopiazonic acid; ergot-like alkaloid; dereplication; HRMS
1. Introduction
The ergot-like alkaloid cyclopiazonic acid (α-cyclopiazonic acid, α-CPA) is an indole-hydrindane-
tetramic acid mycotoxin produced by many fungal species in the Ascomycete genera Penicillium and
Aspergillus. α-CPA was first isolated from a liquid culture of Penicillium cyclopium Westling in 1968, as
the main toxic compound of this microorganism [1]. Afterwards, in 1973, Ohmomo et al. [2] reported
its production by a strain of Aspergillus versicolor. In 1977, it was also demonstrated that α-CPA can be
produced by Aspergillus flavus, a prolific food and feed contaminant [3]. Since then, CPA-producing
strains have been identified in other fungal species such as Penicillium griseofulvum, Penicillium commune,
Penicillium chrysogenum, Aspergillus oryzae, Aspergillus fumigatus and Aspergillus tamarii [4–7].
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A gene cluster for the biosynthesis of α-CPA, containing three essential genes, was identified
in the genome of A. flavus and A. oryzae, situated adjacent to the aflatoxin gene cluster [8,9]. α-CPA
is biosynthesized from three precursors including a tryptophan residue, two units of acetic acid
and an isoprenoid moiety (dimethylallyl diphosphate—DMAPP) in a three-enzyme biochemical
pathway. Through this short metabolic pathway, two biosynthetic intermediates are generated,
cyclo-acetoacetyl-L-tryptophan (cAATrp) and β-cyclopiazonic acid (β-CPA), by consecutive action of
three enzymes, CpaS, CpaD and CpaO. The hybrid two-module polyketide synthase-nonribosomal
peptide synthetase (PKS-NRPS), i.e., CpaS (also known as CpaA), is responsible for the formation
of the tetramic acid cyclo-acetoacetyl-L-tryptophan (cAATrp). cAATrp is then prenylated by the
prenyltransferase CpaD (also known as dmaT), which leads to the generation of β-CPA, the ultimate
tricyclic precursor of α-CPA. The final conversion of β- to α-CPA is catalyzed by the putative
monoamine cyclo-oxidase CpaO (also known as maoA) in a redox reaction forming two rings (ring C
and D) [10,11].
The biochemical mechanism beyond the toxicological profile of α-CPA is proved to be its specific
ability to inhibit sarco/endoplasmic reticulum Ca2+-ATPase (SERCA) in different tissues and cell
types [4,12]. Hence, α-CPA is considered one of the few potent, selective and reversible SERCA
inhibitors, another example being thapsigargin [13]. SERCA is an active membrane pump responsible
for the transfer of Ca2+ ions from the cytosol of the cell to the lumen of the sarco/endoplasmic
reticulum, thus maintaining a low concentration of free calcium ions in the cytosol. Physiologically,
these levels of intracellular calcium are essential for housekeeping activities of each cellular entity,
like cell signaling, proliferation, differentiation and muscle contraction-relaxation. For this reason,
SERCA blockage by α-CPA disrupts the normal intracellular calcium gradient and eventually leads
to cell damage and death. Although the main target organs of CPA poisoning seem to be skeletal
muscle, hepatic tissues and spleen, several animal studies have also reported pathological lesions in
the kidney, pancreas, heart and gastro-intestinal tract [14,15]. Moreover, it has been demonstrated
that CPA exposure can be associated with several neurological symptoms like hypokinesia, catalepsy,
hypothermia, tremors, convulsions, cessation of food intake and resulting cachexia [16]. In general,
α-CPA is not considered an acute mycotoxin due to its relatively high LD50 ranges in rats (30–70 mg/kg)
and because of the benign nature of the intoxication [17]. Although confirmed CPA-mycotoxicoses
have not been reported in humans, it was speculated that CPA exposure may be linked with “kodo
poisoning,” a toxic syndrome characterized by nausea, vomiting, depression and unconsciousness
after intake of CPA-contaminated Kodo millet [18].
The risk of human exposure to α-CPA could arise from the consumption of contaminated food
commodities. α-CPA has been found to contaminate various grains and seeds, as well as different
food matrices such as cheese, nuts and meat products [19–22]. Furthermore, this mycotoxin has
been reported in milk and eggs, most likely due to animal consumption of contaminated feeds [23].
The importance of α-CPA as a toxic contaminant of different foodstuffs has been neglected and masked
by other concurrent mycotoxins such as aflatoxins, especially when co-occurrence of CPA and aflatoxins
has been observed [24–28].
Based on our literature review, since 1968 when α-CPA was first isolated, approximately 30
cyclopiazonic acid (CPA)-type alkaloids have been reported in different fungal extracts of aspergilli
and penicillium (Figure 1; Table 1). These naturally occurring CPA analogues, containing the tetramate
moiety as key structural motif, are characterized by some minor structural variations, and all belong
to indole or oxindole (indolinone) subclasses of alkaloids. Very soon after the α-CPA discovery,
Holzapfel et al. [29] reported the identification of two other CPA derivatives: β-CPA (also termed
bis-secodehydrocyclopiazonic acid) and α-CPA imine. Later on, iso-α-CPA, the isomer of α-CPA,
was structurally characterized in A. flavus [30]. Very recently, a new CPA derivative, pseuboydone
E, has been isolated in Pseudallescheria boydii [31].The above-mentioned metabolites, namely α-CPA,
iso-α-CPA, β-CPA, α-CPA imine, cAATrp and pseuboydone E, are the only CPA derivatives belonging
to the indole subclass of CPA-type alkaloids (Figure 1A). All the remaining analogues, i.e., 2-oxoCPA,
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speradines, cyclopiamides and aspergillines, are classified in the oxindole subclass of CPA-type
alkaloids. The first member of oxindoles possessing a keto-group in the C2-position of the indole
nucleus is 2-oxoCPA; its presence has been reported in A. oryzae [32,33]. The first N-methylated
pentacyclic oxindole analogues of α-CPA, speradine A and 3-hydroxyl-speradine A were isolated in
fungal cultures of A. tamarii [34,35]. Four other tetracyclic oxindole alkaloids, named speradine B, C,
D and E, were identified from A. oryzae [36]. A rare hexacyclic oxindole alkaloid, speradine F (also
termed penicamedine A), together with two novel tetracyclic oxindoles, speradine G and H, were
characterized in A. oryzae isolated from river sediments in China [37,38] (Figure 1B). In the literature,
the nomenclature of oxindoles has been utilized incorrectly. For example, Ma et al. [39] reported the
identification of speradine B, C and D from a sponge-derived strain of A. flavus, but these molecules
do not correspond with metabolites previously described by Hu and coworkers [36]. Speradine B
and D from Ma et al. [39] actually correspond with speradine F and C, respectively, as described by
Hu et al. [37]. Speradine C reported in Ma et al. [39] was actually a new compound possessing an
unprecedented 6/5/6/5/5/6 hexacyclic system with a unique 4-oxo-1,3-oxazinane ring. In order to
differentiate the metabolite previously isolated by Hu et al. [36], we decided to name this compound
speradine I. Afterwards, five highly oxygenated CPA-related alkaloids, aspergillines A−E (Figure 1C),
all having a rigid and sterically congested hexacyclic 6/5/6/5/5/5 indole-tetrahydrofuran-tetramate
scaffold, were isolated from Aspergillus versicolor [40]. Aspergillines B and E possess a butanoic acid
methyl ester moiety, whereas aspergilline C contains an extra isoprenoid moiety attached to the indole
nucleus (Figure 1C). In addition, another group of CPA-related oxindoles, named cyclopiamides A−J,
were isolated from a deep-sea-derived strain of Penicillium commune [41,42] (Figure 1D). Cyclopiamides
H and I isolated in P. commune prove to be the same chemical entities with speradine B and aspergilline
D, respectively. To avoid future confusion regarding the nomenclature of the CPA-related alkaloids,
we suggest they are named as they were discovered chronologically (Figure 1; Table 1).
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Table 1. CPA-type alkaloids identified in different fungal sources.
Compound Name Formula Exact Mass Source Reference
1 α-CPA C20H20N2O3 336.1474 Various Aspergillus and Penicillium species [1,3,29]
2 Iso-α-CPA C20H20N2O3 336.1474 Aspergillus flavus [30]
3 β-CPA C20H22N2O3 338.1630 Various Aspergillus and Penicillium species [8,9,29]
4 cAATrp C15H14N2O3 270.1004 Various Aspergillus and Penicillium species [8–11]
5 α-CPA imine C20H21N3O2 335.1634 Penicillium cyclopium [29]
6 Pseuboydone E C19H20N2O3 324.1474 Pseudallescheria boydii [31]
7 2-oxoCPA C20H20N2O4 352.1423 Aspergillus oryzae [32,33]
8 Speradine A C21H22N2O4 366.1580 A. tamarii, A. oryzae [33,34]
9 3-OH-speradine A C21H22N2O5 382.1529 A. tamarii [35]
10 Speradine B C16H18N2O3 286.1317 A. oryzae, A. flavus [36,39]
11 Speradine C C20H22N2O5 370.1529 A. oryzae, A. flavus [36,39]
12 Speradine D C20H22N2O6 386.1478 A. oryzae [36]
13 Speradine E C20H18N2O5 366.1216 A. oryzae [36]
14 Speradine F (Pencamedine A) C21H22N2O7 414.1427 A. oryzae, P. commune, A. flavus, P. camemberti [37–39,41]
15 Speradine H C20H18N2O4 350.1267 A. oryzae, P. commune [37,41]
16 Speradine I C21H22N2O7 414.1427 A. flavus [39]
17 Aspergilline A C19H20N2O6 372.1321 A. versicolor [40]
18 Aspergilline B C23H26N2O8 458.1689 A. versicolor [40]
19 Aspergilline C C24H28N2O6 440.1947 A. versicolor [40]
20 Aspergilline D (Cyclopiamide I) C21H24N2O7 416.1584 A. versicolor, P. commune [41,42]
21 Aspergilline E C25H30N2O9 502.1951 A. versicolor [40]
22 Cyclopiamide A C16H14N2O2 266.1055 P. cyclopium, P. commune, A. flavus [39,41,42]
23 Cyclopiamide B C20H20N2O4 352.1423 P. commune [41]
24 Cyclopiamide C C19H18N2O4 338.1267 P. commune [41]
25 Cyclopiamide D C19H16N2O4 336.1110 P. commune [41]
26 Cyclopiamide E C20H17N3O2 331.1321 P. commune [41]
27 Cyclopiamide F C15H12N2O2 252.0899 P. commune [41]
28 Cyclopiamide G C15H16N2O3 272.1161 P. commune [41]
29 Cyclopiamide H C16H18N2O3 286.1317 A. oryzae, P. commune, A. flavus [36,39,41]
30 Cyclopiamide J C22H24N2O7 428.1584 P. commune [41]
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Since Aspergillus flavus is an important mycotoxigenic mold, and a very frequent food and feed
contaminant with ubiquitous nature, the probability of human and animal exposure to CPA, as well as
its associated health hazard, is higher compared to other fungal species. On the other hand, one method
for preventing aflatoxin contamination of crops is by introducing a non-aflatoxigenic competitor strain
of A. flavus to compete with natural aflatoxin-producing fungi. Although this approach may reduce
aflatoxin levels in food and feed commodities, the accumulation of other mycotoxins such as CPA has
been observed [43]. In this regard, it is of utmost importance to thoroughly investigate this fungus for
its capability to produce known and yet unknown CPA-type alkaloids. This can be achieved through
a dereplication strategy based on accurate mass high resolution mass spectrometry (HRMS) and
fragmentation data [44]. Nowadays, accurate mass measurements, isotope-model fitting, tandem mass
spectrometry (MS/MS) spectra and chemical databases are integrated in single software packages,
thus allowing a fast and aggressive dereplication of known metabolites (Figure 2). A careful study of
the fragmentation pattern of known compounds can be used to help detect and identify novel and
previously unreported analogues. Hence, the main aim of this work was to investigate the diversity of
the CPA family of alkaloids in different strains of A. flavus by accurate mass HRMS, thereby building
knowledge towards a better assessment of the global A. flavus mycotoxin burden.
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Figure 2. Dereplication workflow of already reported CPA‐related alkaloids by using MasterViewTM 
software as an  integrated package displaying: Extracted chromatogram  (RT—retention  time), mass 
accuracy  (error—ppm), relative quantity  (area—arbitrary units),  isotope‐model  fitting and  tandem 
mass spectrometry (MS/MS) spectra. 
Figure 2. Dereplication workflow of already reported CPA-related alkaloids by using MasterViewTM
software as an integrated package displaying: Extracted chromatogram (RT—retention time), mass
accuracy (error—ppm), relative quantity (area—arbitrary units), isotope-model fitting and tandem
mass spectrometry (MS/MS) spectra.
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2. Results
2.1. Identification of Indole Cyclopiazonic Acid (CPA)-Type Derivatives
A dereplication approach based on accurate mass HRMS data, combined with a careful
examination of fragmentation spectra, was applied to ascertain the presence of previously identified
CPA-type alkaloids and to establish an unambiguous identification strategy for further screening work.
The employed analytical methodology involves an untargeted data acquisition (consisting of full scan
time-of-flight (TOF) HRMS survey and information-dependent acquisition, (IDA) MS/MS scans) and
the processing of data using both targeted and untargeted approaches. An α-CPA reference standard
was available, and therefore, this compound was identified in the fungal extracts by comparison of
retention time, accurate mass HRMS and HRMS/MS data with the reference standard. A careful
investigation and interpretation of α-CPA fragmentation data was the basis for the identification of
other CPA-type alkaloids as described below.
A perfect match was observed between the α-CPA MS/MS spectrum of the reference standard
and that of the putative CPA in A. flavus extracts. A typical MS/MS spectrum of the protonated
α-CPA ion ([m + H]+/z 337.1536; ∆ = −0.9 ppm) is shown in Figure 3A. The observed fragmentation
pattern is also in accordance with reports from previous studies [1,45,46]. This spectrum, apart from
the parent ion ([m + H]+/z 337), also shows some prominent fragment ions at m/z 196, 182, 167, 154
and 140 together with their “sibling species” at m/z 197, 181, 168, 155 and 141, thereby corroborating
the findings from Holzapfel [1]. Generation of these metastable species most likely is achieved by
ejection of a hydrogen atom from the main original fragment or vice versa [1]. For example, at
least a part of the m/z 154 signal is yielded by proton ejection from m/z 155. High resolution mass
measurements revealed that fragments at mass 154 and 155 correspond to the chemical formula of
C11H8N+ and C11H9N+, respectively. Based on their chemical composition, these fragments must
contain the indole system and three additional carbon atoms, resulting from the cleavage of the C4-C5
and C10-C11 bonds of ring D. The fragment ion at m/z 196 has the chemical composition of C14H14N+
and corresponds to the fragment ion 154 with three additional carbon atoms. This ion (m/z 196) arises
by cleavage of the C4-C5 and C9-C10 bonds of ring D. Accurate mass measurements showed that the
ion at mass 182 corresponds to the chemical formula C9H12NO3+. This fragment ion contains all the
oxygen atoms of the parent ion, and therefore represents the tetramic acid moiety of the molecule as
depicted in Figure 3A. The ion with m/z 167 is most likely formed by further ejection of a methyl group
(-CH3) from the ion at m/z 182, whilst the mass 130 represents the indole nucleus of the molecule.
On the other hand, the ion at m/z 140 represents ring E of α-CPA with the hydroxy-ethyl moiety
(=C(OH)CH3) attached. Moreover, an ion with 18 Da difference (m/z 319) from the parent ion can be
seen in the spectrum, which is attributed to the loss of a water molecule. β-CPA ([m + H]+/z 339.1700;
∆ = −0.9 ppm), also known as bissecodehydrocyclopiazonic acid, is a biosynthetic precursor of α-CPA
with opened rings C and D. The MS/MS spectrum of this compound was similar to that previously
reported by Holzapfel et al. [29], showing a peak at m/z 283 (C16H15N2O3+) which corresponds to a
loss of the (CH3)C=CH2- group from the parent ion (Figure 3B). Another prominent peak, with m/z 198,
can be seen in the spectrum, representing the indole nucleus together with the dimethylallyl moiety.
This ion was generated by the cleavage of the C4-C5 bond. Moreover, accurate mass measurements of
the product ion 198 revealed a chemical composition of C14H16N+, excluding oxygen functionalities
which further supports its structural formula as depicted in Figure 3B. In the same spectrum, three
other fragment ions can be seen at m/z 156 (C11H10N+), 155 (C11H9N+) and 154 (C11H8N+), which were
also observed in the mass spectrum of α-CPA but with different abundances. The presence of these
tricyclic ions in the fragmentation pattern of the seco-molecule β-CPA can be explained by the fact that
initial fragments of the precursor ion subsequently undergo a cyclization step of the two side chains of
the indole system. More precisely this cyclization process is carried out by formation of the C4-C11
bond in the fragment ion at m/z198 and closure of ring C (Figure S1). The ion at m/z 144 (C10H10N+),
most likely arises from the ion of mass 198 by loss of the isoprenoid moiety ((CH3)C=CH2-).
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dependent acquisition) mode using a CE (collision energy) of 35 V with a collision energy spread (CES)
of 15 V.
α-CPA imine is a very similar chemical entity to α-CPA, in which the hydroxyl functionality is
substituted with an amino group. The fact that these metabolites are closely related to each other is
also demonstrated by their shared fragmentation behavior. The MS/MS spectrum of α-CPA imine
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([m + H]+/z 336.1707; ∆ < 0.1 ppm) showed ions with m/z 319, 196, 154, 155 and 130 identical with
those observed for α-CPA (Figure 3C). The fragment ions containing the amino group in their structure,
namely m/z 181, 180 and 139, showed 1 Da difference with their corresponding fragments from
the α-CPA molecule, which is consistent with the mass difference between -OH and -NH2 groups.
The biosynthetic intermediate of α-CPA, cyclo-acetoacetyl-L-tryptophan (cAATrp), showed only one
prominent fragment peak at m/z 130, corresponding to the indole nucleus of this metabolite (Figure 3D).
Pseuboydone E was not detected in our samples.
2.2. Identification of Oxindole CPA-Type Derivatives
2-oxo-CPA is an oxygenated derivative of α-CPA. More precisely, it is an oxygen atom in the
form of a keto-group that is added at the C2 position of the indole nucleus of the α-CPA. The MS/MS
spectrum of 2-oxo-CPA ([m + H]+/z 353.1504; ∆ = 0.8 ppm) showed, besides the precursor ion at
[m + H]+/z 353, characteristic fragments at m/z 335, 212, 182, 170, 154, 146 and 140 (Figure S2A). Since
2-oxo-CPA has an extra oxygen atom in its structure compared to its precursor, α-CPA, there is a
mass difference of 16 Da between the two compounds. In this regard, all fragment ions in which the
oxygenated indole system is incorporated show this 16 Da difference with their corresponding α-CPA
fragments. Hence, fragment ions at m/z 335, 212, 170 and 146 are the oxygenated analogues of the
fragment ions at m/z 319, 196, 154 and 130 in the MS/MS spectrum of α-CPA. On the other hand,
peaks at m/z 182 and 140, which contain the tetramate moiety are identical to their corresponding
fragments in the α-CPA MS/MS spectrum. The presence of the tricyclic fragment ion at m/z 154 may
be justified by a possible cleavage of the hydroxyl group at C2 position of the ion at m/z 170.
Speradine A also known as 1-N-methyl-2-oxo-CPA, is a methylated derivative of 2-oxo-CPA
first reported in a marine-derived isolate of A. tamarii. The fragmentation pattern of speradine A
([m + H]+/z 367.1648; ∆ = −1.0 ppm) was similar to that of 2-oxo-CPA and α-CPA (Figure S2B). Due to
the extra N-methyl group attached in the indole nucleus, speradine A has a 14 Da mass difference with
2-oxo-CPA. This 14 Da mass difference can be observed in all the typical fragments of speradine A
(m/z 349, 325, 226 and 160) as compared to the MS/MS spectrum of 2-oxo-CPA. It is worth noting
that HRMS and MS/MS data observed in our study for speradine A are in accordance with previous
reports [33,34]. 3-Hydroxy-speradine A ([m + H]+/z 383.1610; ∆ = 2.0 ppm) is a hydroxylated derivative
of speradine A, in which a hydroxyl functionality is added in the C3 position of the speradine A. The
extraction of the mass corresponding to 3-hydroxy-speradine A, i.e., [m + H]/z 383.1610 resulted in
three different peaks at RT 5.03, 5.76 and 5.97 min (Figure 4). The fragmentation pattern of the peaks at
RT 5.76 and 5.97 min corresponded to the 3-OH-speradine A, whereas the metabolite eluting at RT
5.03 min had a slightly different fragmentation pattern, suggesting that the hydroxyl group may be
attached at a different position. MS/MS spectrum of 3-OH-speradine A is depicted in Figure S2C. The
two peaks with the mass of precursor ion and fragmentation pattern corresponding to 3-OH-speradine
A can be explained by existence of different diastereoisomers.
Speradine B ([m + H]/z 287.1391; ∆ = −0.4 ppm) eluted at two different retention times, 4.15
and 4.99 min, both displaying identical MS/MS spectra with a typical fragmentation pattern for
cyclopiazonic acid derivatives missing ring E (Figure S3A; Figure 4). The elution of speradine B
at two different peaks can be justified by the existence of the same chemical compound in several
stereoisomeric forms.
Speradine C has a very similar core structure with speradine B, except that in the N-6 position of
speradine C a diketide moiety is attached. Based on this structural analogy, speradine C ([m + H]+/z
371.1600; ∆ = −0.2 ppm) underwent a very similar mode of fragmentation with that of speradine B, as
depicted in Figure S3B. MS/MS spectrum of speradine C showed a peak at m/z 353, which corresponds
to the loss of a water molecule (18 Da) from the parent ion. The fragment ion at m/z 287 represents
the molecular ion of speradine B, which is generated after the loss of the diketide moiety from the
N-6 position of speradine C. The rest of the fragments’ ions (i.e., m/z 226, 184, 169, 156 and 129) are
identical with those in the fragmentation pattern of speradine B.
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Speradi e D is a cl sely relate etabolite to speradine C showing a typical pathway of
fragmentation for cyclopiazonic acids missing ring E and ossessing a saturated ring C (Figure S3C).
In the sa e fashion as speradine C, initially the OH group speradine D ([m + H]/z 387.1554;
∆ = 1.0 ppm) in the C3 position was lost through the elimination of a water molecule (−18 Da);
subsequently, a cleavage of the N6-linked side chain occurred. The downstream fragmentation
pathway of speradine D was identical with that of speradine B and C.
Speradine F is a highly oxygenated hexacyclic oxindole-tetrahidrofuran-tetramate metabolite
having a very similar structural scaffold as the aspergillines isolated in fungal extracts of A. versicolor.
Since peradine F is an N-methyl- -oxo-indole with a atu ated ring C, in the MS/MS spectrum of
this compound ([m + H]+/z 415.1497; ∆ = −1.9 ppm), we ould see the typ cal mass fragments for this
subgroup of oxindoles like m/z 269, 226, 184 and 169, as were observed in the fragmentation pattern
of speradine B, C and D (Figure S3D). Besides these typical ions, two other ions could be assigned in
this MS/MS spectrum, namely the fragment ions at m/z 397 and 379. The fragment ion at m/z 397 is
attributed to the disruption of ring F (tetrahydrofuran ring) as a water molecule, whilst the 379 ion is
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generated from the subsequent loss of a water molecule from the C7-linked side chain. On the other
hand, speradine H ([m + H]+/z 351.1341; ∆ = −1.1 ppm) is a tetracyclic N-methyl-2-oxo-indole with
an unsaturated ring C, thus exerting some typical fragments for this subgroup of oxindoles such as,
m/z 267, 250, 222, 207 and 194 (Figure S3E).
Cyclopiamide A ([m + H]+/z 267.1132; ∆ = −0.7 ppm) and cyclopiamide B ([m + H]+/z 353.1498;
∆ = −0.8 ppm), both tetracyclic N-methyl-2-oxo-indoles with an unsaturated ring C, shared the
same fragmentation pathway as speradine H (Figure S4A,B). Cyclopiamide C ([m + H]+/z 339.1339;
∆ = −0.2 ppm), cyclopiamide D ([m + H]+/z 337.1178; ∆ = −2.9 ppm) and cyclopiamide F ([m + H]+/z
253.0966; ∆ = −3.0 ppm), all belonging to the subgroup of 2-oxo-indoles with an unsaturated ring C,
shared the same fragmentation pathway, with the most prominent fragments at m/z 253, 236, 208, 180
and 165 (Figures S4C,D and S5B). Cyclopiamide E is actually a pentacyclic N-methyl-2-oxo-indole with
a very characteristic ring E, a 4-oxo-1,3-diazine, which seems to influence the fragmentation pattern
of the parent ion. Hence, although it belongs to N-methyl-2-oxo-indoles with unsaturated ring C,
cyclopiamide E ([m + H]+/z 332.1409; ∆ = 2.7 ppm) showed a unique pattern of fragmentation with
the most prominent fragment peaks at m/z 317, 288, 274 and 249 (Figure S5A).
Cyclopiamide G is a 2-oxo-indole with a saturated ring C, thus sharing some key structural
fragments (m/z 212 and 170) with 2-oxo-CPA. Furthermore, in the MS/MS spectrum of cyclopiamide
G ([m + H]+/z 273.1233; ∆ = −1.5 ppm), an ion with m/z 255 demonstrates the loss of a hydroxyl
group from the C3 position of the parent molecule (Figure S5C). Cyclopiamide J ([m + H]+/z 429.1656;
∆ = −0.9 ppm) underwent a similar fashion of fragmentation as speradine F, because they share
almost the same chemical scaffold with a small difference in the C7-linked side chain. Hence,
the typical fragments at m/z 397, 379, 269, 226, 184 and 169 can be observed in the MS/MS spectrum
of cyclopiamide J (Figure S5D). None of the aspergillines could be detected in the different strains
of A. flavus.
2.3. Identification of Previously Unreported CPA-Type Derivatives
To investigate other derivatives that were not included in our list of target CPA-type alkaloids, the
MS/MS data were checked for the presence of diagnostic ions of this class of compounds (Table S2).
Besides the above known compounds, this untargeted analysis uncovered two other metabolites,
m/z 335.1395 and m/z 369.1439, which shared the same fragmentation pattern and whose MS/MS
spectra encompassed diagnostic ions of the CPA-type alkaloids. Accurate mass measurements revealed
that the metabolite at [m + H]+/z 335.1395 (∆ = 1.4 ppm) corresponds to the chemical formula
C20H19N2O3, possessing two protons less than the original molecule of α-CPA. These two protons’
(2 Da) difference implies an extra double bond in the chemical scaffold of α-CPA. The location of this
double bond is most likely in ring C of the molecule because fragment ions at m/z 130 (ring A and B),
m/z 168 and 182 (ring D and E) are the same as described in the MS/MS spectrum of α-CPA, whilst the
fragments at m/z 194, 223, 251, 317 containing ring C in their structure exhibit that 2 Da difference with
their corresponding fragments from the α-CPA MS/MS spectrum (Figure S6A). On the other hand,
the metabolite eluting at RT 5.5 min had the chemical formula C20H21N2O5 ([m + H]+/z 369.1439;
∆ = −1.6 ppm). Chemical composition as well as fragmentation pattern of this metabolite provided
enough evidence to be assigned as a C3-hydroxylated analogue of 2-oxo CPA (Figure S6B).
2.4. Screening of CPA-Type Alkaloids in Different A. flavus Strains
Based on the data described above, a screening of CPA-type alkaloids was performed on a
set of 55 A. flavus strains. In total, 22 CPA-type alkaloids were identified in extracts of the strains
investigated, demonstrating the great potential of this ubiquitous fungus in producing secondary
metabolites (Table 2). Of these metabolites, 13 have been previously reported in other fungi, but here
they are reported for the first time in A. flavus. We also report the occurrence of two novel CPA-related
metabolites in these samples.
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Table 2. CPA-type alkaloids detected in our study.
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0038 ++ ++ ++ + ++ + - - - - ++ - - - ++ + - + + - ++ ++
0141 + - - - + ++ + - + - - - - + - - - - - - - -
0144 +++ ++ - ++ ++ + + - - - - - - ++ ++ + - + + - ++ ++
0150 +++ ++ ++ ++ ++ + + - - - - - - - ++ - - ++ + - ++ ++
0151 - - - - - - - - - - - - - - - - - - - - - -
0167 +++ ++ + ++ ++ - - - - - - - - - - - - - - - ++ ++
0283 ++ ++ - ++ ++ ++ ++ ++ ++ + ++ - ++ ++ ++ + - + + ++ ++ ++
0295 ++ ++ - ++ ++ ++ +++ ++ ++ + ++ ++ ++ ++ + + ++ + + ++ ++ ++
1000F +++ ++ - ++ ++ - - - - - - - - - - - - + - - ++ ++
1006 ++ ++ ++ ++ + ++ ++ - - - - - - + + + - + - - ++ ++
1020 +++ ++ ++ ++ + - - - - - - - - - ++ - - ++ + - ++ ++
1021 ++ ++ + + ++ - - - - - - - - - - - - - - - - ++
1055 +++ + + ++ ++ - - - - - - - - - ++ ++ - ++ + - ++ ++
1071 ++ ++ - - + - - - - - - - - - + - - + - - + +
1098 ++ + - ++ - - - - - - - - - - + - - ++ - - ++ +
1118 - - - - - - - - - - - - - - - - - - - - - -
1187 ++ ++ - ++ ++ - - - - - - - - - ++ - - - - - ++ ++
1299 ++ ++ ++ ++ ++ - - - - - - - - - + - - + + - ++ ++
1356 ++ - ++ ++ ++ ++ - - - - - - - - + - - ++ + - ++ ++
1357 ++ ++ - ++ + ++ ++ ++ - - - ++ ++ - ++ - - + - ++ + -
1533 ++ ++ - ++ ++ - - - - - - - - - ++ - - + + - ++ ++
1534 ++ ++ - + - - - - - - - - - - - - - + - - - -
1540 ++ + - + ++ ++ + - - - - - - - - - - - - - + ++
1541 ++ - - ++ - - - - - - - - - - ++ - - - - - - -
1543 ++ - - ++ - ++ ++ + + - - - - + - - - + - - - +
1544 ++ ++ - ++ ++ ++ ++ ++ ++ ++ ++ ++ ++ ++ + - ++ ++ - ++ ++ ++
1545 +++ ++ ++ ++ ++ - - - - - - - - - ++ + - ++ + - ++ ++
1547 ++ ++ - ++ - ++ ++ ++ ++ - ++ - ++ ++ - - - - - ++ ++ -
1552 ++ - - - + ++ ++ - + - - - - - - - - - - - - +
1553 ++ + + + ++ - - - - - ++ - - - ++ - - ++ + - ++ ++
1554 +++ + + ++ ++ + - - - - - - - - ++ - - - - - ++ ++
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1557 ++ ++ - ++ + ++ ++ ++ ++ - ++ ++ ++ ++ - - ++ - - ++ ++ -
1558 ++ ++ - ++ ++ - - + - - - - - - ++ + - + + - ++ ++
1559 +++ ++ + ++ ++ - - - - - - - - - ++ - - ++ + - ++ ++
1565 ++ ++ - + + - - - - - - - - - + + - - - - ++ ++
1566 +++ ++ - + ++ - - - - - - - - - - - - - - - ++ ++
1568 - - - - - - - - - - - - - - - - - - - - - -
1571 ++ ++ ++ ++ + ++ +++ ++ ++ + + - ++ ++ + - + + - ++ + ++
1573 +++ ++ - + + - - - - - - - - - ++ + - + + - ++ ++
1574 +++ ++ ++ + ++ - - - - - - - - - + + - ++ + - ++ ++
1575 ++ ++ - ++ - ++ ++ ++ ++ - ++ ++ ++ ++ - - ++ - - ++ ++ -
1576 ++ ++ + ++ ++ ++ ++ - + - - - - - + + - + + - ++ ++
1578 +++ ++ ++ ++ ++ - - - - - - - + - ++ + - + - - ++ ++
1591 ++ ++ - ++ ++ ++ +++ ++ ++ - ++ ++ ++ ++ + + + + - ++ ++ ++
1626 ++ ++ + ++ ++ ++ ++ - + - - - - - ++ + - + + - ++ ++
1637 ++ ++ + ++ ++ ++ ++ ++ ++ + ++ - ++ ++ ++ - ++ + + + + ++
2000 ++ - - ++ ++ - - - - - - - - - ++ - - - - - + ++
2001 ++ ++ + + + - - - - - - - - - ++ - - ++ - - + ++
2033 +++ ++ ++ + ++ - - - - - - - - - ++ + - + + - ++ ++
2035 +++ ++ - - ++ - - - - - - - - ++ - + - + + - ++ ++
2114 - - - - - - - - - - - - - - - - - - - - - -
2115 +++ ++ ++ ++ ++ - - - - - - - - - - - - + + - ++ -
2118 ++ - ++ + ++ + - - - - - - - - + - - ++ + - ++ ++
2524 +++ ++ - + ++ - - - + - - - - - ++ + - + + - ++ ++
2711 +++ - - ++ ++ - - - - - - - - - + - - + - - ++ ++
“+”, Peak area ≤ 104; “++”, 104 < Peak area < 106; “+++”, Peak area ≥ 106; “-“ not detected; SRRC-Southern Regional Research Center; CPA-cyclopiazonic acid; The presence of
compounds was verified with MS/MS spectra as described under Sections 2.1–2.3.
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3. Discussion
Chemically, α-CPA is a hybrid prenylated indole alkaloid, structurally characterized by a rigid
pentacyclic (6/5/6/5/5) skeleton bearing a unique heterocyclic pyrrolidine-2,4-dione (tetramic acid)
motif as the main part of its pharmacophore. This mycotoxin does not contain any O-methyl or
N-methyl groups in its structural scaffold and is characterized by the ability to form an intramolecular
hydrogen bond due to its keto-enol tautomerism. Since α-CPA is a very well-known mycotoxin,
its identification in A. flavus fungal extracts was straightforward, and was also supported by data
from previous work [1,3,45,46]. The same mode of fragmentation was observed in the MS/MS
spectrum of α-CPA and those of other indole derivatives (β-CPA, α-CPA imine and cAATrp) (Figure 3).
The identification of these compounds was also straightforward, as they share the same scaffold with
α-CPA. On the other hand, the identification of the oxindole CPA-type alkaloids was more complex
due to their high chemical diversity in terms of different structural scaffolds. Moreover, this subclass
of alkaloids is less studied compared to α-CPA itself and other indole derivatives. For this reason,
and also to simplify the identification, we subdivided the oxindole subclass of CPA-type alkaloids in
four different chemical groups: (i) 2-oxindoles with saturated ring C (2-oxo-CPA and cyclopiamide
G); (ii) 2-oxindoles with unsaturated ring C (cyclopiamide C, cyclopiamide D and cyclopiamide F);
(iii) N-methyl-2-oxindoles with saturated ring C (speradine A, 3-hydroxy-speradine A, speradines B-D,
speradine F, cyclopiamide H and cyclopiamide J); and (iv) N-methyl-2-oxindoles with unsaturated
ring C (speradine E, speradine H, cyclopiamide A, cyclopiamide B, and cyclopiamide E). The MS/MS
spectra demonstrated that all the metabolites belonging to the same chemical group share two or
three typical fragments that reflect the core structure of the respective chemical group (Table S2),
and which can therefore be used as diagnostic ions. This chemical classification and the diagnostic
ion approach facilitated the dereplication of oxindoles included in our study, and it is also a useful
methodology for the identification of yet unknown CPA-type oxindoles. Besides accurate mass
measurements and MS/MS data, other analytical parameters like elution order and isotope-model
fitting prove to be complementary identification aids. For instance, in our study, speradine A eluted
between α-CPA and 2-oxo-CPA, which actually represents the same elution pattern as reported by
other researchers [33]. Similar successful dereplication approaches based on TOF technologies have
been reported previously [44,47,48].
Production of polyketide-amino acid hybrid metabolites, as is the case for α-CPA, is catalyzed by
PKS-NRPS enzymes. PKS-NRPSs are complex and multi-domain enzymes characterized as having
the ability to synthesize highly diverse chemical groups of secondary metabolites [49]. The genome
of A. flavus is predicted to harbor two PKS-NRPS hybrid gene clusters. One (cluster #55) is the gene
cluster of CPA [9], while the other one (cluster #23) has been shown to be responsible for the production
of a series of 2-pyridones [50,51]. As indicated above, the CPA gene cluster in A. flavus NRRL 3357
contains only three functional genes and a Zn2Cys6 transcription factor-encoding gene (ctfR1), which
seems to be inactive [10]. On the other hand, our study demonstrated a huge chemical diversity within
the CPA family of mycotoxins. Therefore, different A. flavus strains have the ability to produce many
more metabolites apart from α-CPA and its precursors (Table 2). Although it is hard to predict if all
the identified metabolites are linked with the CPA gene cluster, the chemical scaffold resemblance
strongly suggests a convergent biochemical origin. It is likely that the genetic material reported
for the CPA gene cluster in NRRL 3357 is not sufficient to explain the chemical diversity found in
other strains of A. flavus. Hence, most likely other A. flavus strains like S295, S283, S1637, and S1544
possess additional genes within their CPA clusters that may catalyze extra biochemical steps in the
biosynthetic pathway of CPA. This concept was already demonstrated in A. oryzae NBRC 4177 in the
case of 2-oxoCPA. A cytochrome P450 oxidase gene (cpaH) located within a CPA cluster in NBRC 4177
was shown to mediate the conversion of α-CPA to 2-oxoCPA [32]. In the same fashion, it was reported
that a strain of A. tamarii (NBRC 4099) harbors the gene cpaM, which encodes for a N-methyltransferase
involved in the synthesis of 1-N-methyl-2-oxoCPA (speradine A) from 2-oxoCPA [33]. The inability of
speradine A production in A. oryzae is caused by mutations or partial deletions in cpaM. In analogy
Toxins 2017, 9, 35 15 of 21
with aforementioned findings, we can speculate that the homolog genes of cpaH and cpaM may be
also present in the CPA gene cluster of 2-oxo-CPA and speradine A-producing strains of A. flavus.
In this regard, the CPA gene cluster seems more genetically diverse than expected, especially when
we consider the identification of other complex CPA-type alkaloids like speradine F, cyclopiamide E,
cyclopiamide J, the aspergillines, etc. Additional genetic data are needed to support the occurrence
of these metabolites in A. flavus fungal extracts. Nevertheless, we cannot exclude the possibility of
involvement in the CPA-biosynthetic network of enzymes that are encoded by genes located outside
the CPA gene cluster. Moreover, there is also the possibility of non-enzymatic generation of metabolites
under different culture conditions or during various sample treatment procedures.
The tetramic acid structural moiety is a very important nitrogen-containing heterocycle that is
often the pharmacophore to interact with various biological targets, thus it exhibits a wide range of
biological and toxicological activities [52–54]. Apart from α-CPA, 2-oxoCPA and speradine A, for
which the SERCA-blocking activity was clearly demonstrated, the toxicological profile for the rest of
the CPA-type metabolites is unknown [4,12,34]. In this context, it is important both to evaluate the
actual toxicological potential of these CPA-related alkaloids and to get an idea about their contributions
in the overall CPA toxicity. Moreover, there are no data about their occurrences in food and feed
commodities, which further complicates our understanding about human and animal exposure to
CPA contamination. Hence, conducting survey studies of CPA-type mycotoxins in different food and
feed matrices might be necessary to decipher the real impact of CPA contamination in human and
animal health, especially considering the fact that CPA is always overshadowed by concern about
aflatoxin contamination.
One of the main approaches for pre-harvest control of aflatoxin contamination in crops
is the introduction of non-aflatoxigenic A. flavus isolates into agricultural fields to displace
aflatoxin-producing strains. The necessary features for a potential A. flavus strain to be used as
a biocontrol agent include ability to grow rapidly, to be adapted for specific plant colonization, and to
produce sclerotia for long-term survival in the fields [55,56]. From a toxicological point of view, the
only seemingly important feature for a biocontrol strain is the inability to produce aflatoxins. However,
the inability to produce other relevant mycotoxins, among which are α-CPA and our newly identified
CPA analogues, is highly desirable due to the unknown long-term and cumulative toxicological effects
of these metabolites. Thus, a careful screening of these metabolites is obviously very important in
order to avoid any possible inadvertent mycotoxicoses from the introduction of biocontrol agents into
agricultural fields. Also, increased efforts to assess the genetic stability of the A. flavus strains used
in biocontrol products should be undertaken. This is highly relevant since there is now evidence for
a sexual stage in several aflatoxigenic Aspergillus species [57,58]. Hence, the possibility of re-gaining
aflatoxin- and/or CPA-producing properties through sexual recombination is a fact that should not be
neglected. The same concern of exposure to CPA-type mycotoxins can be made regarding A. oryzae
strains which are being used extensively in the food fermentation industry [59].
Data from the present work show a conspicuous presence of CPA and its derivatives in the
different A. flavus strains investigated, and highlight the previously mentioned need for a thorough
assessment of the actual impact of contamination of crops with CPA-type mycotoxins on human and
animal health. Two commercially available biocontrol strains (AF36 and NRRL 21882) were included
in this study. AF36 was originally isolated from a cotton field in Arizona and was approved for
application on cotton in Arizona. Loss of aflatoxigenicity in AF36 is the result of a nonsense mutation
in pksA (aflC), a pathway gene in aflatoxin biosynthesis [60]. AF36 has an otherwise full aflatoxin cluster.
AF36 does have a fully functional CPA cluster, and although it is effective at excluding toxigenic strains
and reducing AF levels, this strain is reported to significantly increase CPA accumulation in food
and feed commodities [61]. This is consistent with our findings which demonstrated the ability of
AF36 to produce α-CPA and a series of other CPA-like alkaloids, including its precursors (cAATrp
and β-CPA), 2-oxoCPA, cyclopiamide C, F, G and the two other previously unreported derivatives
(see 2.3). Remarkably, our data uncovered the presence of the CPA family of mycotoxins in fungal
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extracts of NRRL 21882, which is reported to lack both the aflatoxin and CPA gene clusters [61]. These
findings could support the phenomenon of heterokaryosis and vertical transmission of cryptic alleles
in A. flavus in NRRL 21882. Olarte et al. [62] reported that it is possible for some A. flavus to possess
cryptic alleles, particularly when typically masked genes are amplified because the dominant genome
lacks the gene(s) of interest. Moore et al. [63] were able to amplify and sequence a portion of the
aflW/aflX region in NRRL 21882. This indicates NRRL 21882 may be heterokaryotic with a low-copy
genome possessing cryptic alleles for a functional CPA gene cluster, thereby making this particular
strain a CPA producer even though it is missing the entire subtelomeric region of chromosome 3.
Existence of similar non-parental cryptic alleles has been reported also in other fungal species [64,65].
It is worth noting that besides their toxicological relevance, there is currently a revival of interest
for pharmacological application of CPA-type pharmacophores. As stated above, α-CPA is a specific
nanomolar inhibitor of mammalian SERCA-1. This SERCA-inhibiting activity of α-CPA is being
exploited extensively for various pharmacological purposes. Thus, Kotsubei et al. [66], by using
α-CPA as an experimental inhibitor, demonstrated sufficient differences in active binding sites between
mammalian and bacterial SERCA. These differences in the CPA pocket between mammalian and
bacterial Ca2+-ATPase suggest that a bacterial-specific CPA derivative could be developed, hence
making the bacterial SERCA a potential drug target. Moreover, α-CPA has been shown to possess clear
antiviral activity as well as causing perturbations in cardiac ventricular myocytes [67,68]. Based on
these concepts, CPA-type alkaloids identified in this study, and/or other derivatives which may be
discovered or synthesized in the future, could be useful bioactive scaffolds to be employed in future
pharmacological applications.
4. Conclusions
Accurate mass high resolution mass spectrometry (HRMS), combined with a careful investigation
of fragmentation patterns, proved to be a suitable dereplication strategy for the identification of
cyclopiazonic acid (CPA)-type alkaloids. This approach resulted in our finding 22 CPA-type alkaloids
in A. flavus cultures. Two of these metabolites are new discoveries as they have never been reported.
Though the other 20 compounds have been previously identified in different fungi, 13 of these
metabolites were identified for the first time in A. flavus. These results provide a better insight into the
diversity of CPA-type alkaloids in A. flavus and raise concerns about the extent of the overall A. flavus
mycotoxin problem. The described identification strategy can be applied in programs aiming to assess
the occurrence of this type of mycotoxin in food and feed commodities. Our results also demonstrate
the great potential of A. flavus in producing a myriad of secondary metabolites, highlighting the need
for a more thorough investigation into potential mycotoxicity of non-aflatoxigenic strains that are
currently being used in biocontrol strategies.
5. Materials and Methods
5.1. Chemicals and Materials
Methanol (MeOH) and acetonitrile (ACN), LC-MS grade, were obtained from Biosolve
(Valkenswaard, the Netherlands), whereas HPLC-grade MeOH was from VWR International
(Zaventem, Belgium). Ethyl acetate (EtOAc), dichloromethane (DCM) and acetone (dimethyl ketone
(DMK)) were purchased from Acros Organics (Geel, Belgium). Sigma-Aldrich (Bornem, Belgium)
supplied ammonium formate (HCOONH4). Formic acid (HCOOH, Merck, Darmstadt, Germany)
was used. Ultrapure H2O was produced by a Milli-Q Gradient System (Millipore, Brussels, Belgium).
Ultrafree®-MC centrifugal filter units (0.22 µm) from Millipore (Bedford, MA, USA) were used.
Sigma-Aldrich supplied agar, corn steep solids, dextrose, peptone, sucrose, yeast extract, dipotassium
hydrogen phosphate trihydrate (K2HPO4·3H2O), magnesium sulfate heptahydrate (MgSO4·7H2O),
and iron(II) sulfate heptahydrate (FeSO4·7H2O). Triton X-100, potassium chloride (KCl), and sodium
nitrate (NaNO3) were from Merck.
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5.2. Strains and Growth Conditions
A. flavus strains used in this study are listed in Table S1 as supplementary data. Conidia of
each respective strain were inoculated on solid Wickersham media (≈25 mL of medium per plate,
D = 10 cm) which contains 2.0 g yeast extract, 3.0 g peptone, 5.0 g corn steep solids, 2.0 g dextrose,
30.0 g sucrose, 2.0 g NaNO3, 1.0 g K2HPO4·3H2O, 0.5 g MgSO4·7H2O, 0.2 g KCl, 0.1 g FeSO4·7H2O,
15.0 g agar per litre (pH 5.5). All cultures were incubated at 28 ◦C in the dark for 7 days.
5.3. Sample Preparation
The fungal colonies and agar were cut into small pieces with a scalpel and these were subsequently
transferred to a 500 mL screw-cap Ehrlenmeyer flask. Metabolites were extracted with 30 mL
MeOH:DCM:EtOAc 10:20:30, (v/v/v). The samples were agitated for 60 min on an Agitelec overhead
shaker (J. Toulemonde and Cie, Paris, France). A total of 4 mL of extract was transferred to a
glass tube and evaporated under a stream of nitrogen. The residue was reconstituted with 200 µL
MeOH:ACN:H2O 30:30:40, (v/v/v), and centrifuged in an Ultrafree®-MC centrifugal device for 5 min
at 14,000× g.
5.4. UHPLC-qTOF-MS Analysis
The experiments were carried out using a hybrid Q-TOF MS instrument, the AB SCIEXTripleTOF®4600
(AB Sciex, Concord, ON, Canada), equipped with a DuoSprayTM and coupled to an Eksigent ekspert™
ultraLC 100-XL system. The DuoSprayTM ion source (consisting of both electrospray ionization (ESI)
and atmospheric pressure chemical ionization (APCI) probes) was operated in the positive ESI mode
(ESI+). The APCI probe was used for automated mass calibration using the Calibrant Delivery System
(CDS). The CDS injects a calibration solution matching the polarity of ionization, and calibrates the
mass axis of the TripleTOF® system in all scan functions used (MS and/or MS/MS). The Q-TOF HRMS
method consisted of a full scan TOF survey (dwell time 100 ms, 100–1600 Da) and a maximum number
of eight IDA MS/MS scans (dwell time 50 ms). The MS parameters were as follows: curtain gas (CUR)
25 psi, nebulizer gas (GS 1) 50 psi, heated gas (GS 2) 60 psi, ion spray voltage (ISVF) 5.5 kV, interface
heater temperature (TEM) 500 ◦C, Collision Energy (CE) 10 V and declustering potential (DP) 70 V. For
the IDA MS/MS experiments, a CE of 35 V was applied with a collision energy spread (CES) of 15 V.
An Eksigentekspert™ ultraLC 100-XL system was used for separation. The column was a ZORBAX
RRHD Eclipse Plus C18 (1.8 µm, 2.1 × 100 mm) from Agilent Technologies (Diegem, Belgium). The
mobile phase consisted of H2O:MeOH (95:5, v/v) containing 0.1% HCOOH and 10 mM HCOONH4
(solvent A) and MeOH:H2O (95:5, v/v) containing 0.1% HCOOH and 10 mM HCOONH4 (solvent
B). The gradient elution program for LC-qTOF HRMS analyses was applied as follows: 0–0.5 min:
0% B, 0.5–7 min: 0%–99% B, 7–9 min: 99% B, 9–10 min: 99%–0% B, 10–14 min: 0% B. The flow rate
was 0.4 mL/min. The column temperature was set at 40 ◦C and temperature of the autosampler was
4 ◦C. 5 µL of sample were injected. The instrument was controlled by Analyst® TF 1.6 software, while
data processing was carried out using PeakView® software version 2.0 and MasterViewTM software
version 1.0 (all from AB Sciex).
Supplementary Materials: The following are available online at www.mdpi.com/2072-6651/9/1/35/s1,
Figure S1: Cyclization mechanism of the ions at m/z 156, 155 and 154 in the fragmentation pathway of β-CPA,
Figure S2: MS/MS spectra and structural fragments of: A. 2-oxo-CPA; B. speradine A, and C. 3-hydroxy-speradine
A, Figure S3: MS/MS spectra and structural fragments of: A. speradine B; B. speradine C; C. speradine D;
D. speradine F, and E. speradine H, Figure S4: MS/MS spectra and structural fragments of: A. cyclopiamide
A; B. cyclopiamide B; C. cyclopiamide C, and D. cyclopiamide D, Figure S5: MS/MS spectra and structural
fragments of: A. cyclopiamide E; B. cyclopiamide F; C. cyclopiamide G, and D. cyclopiamide J, Figure S6:
MS/MS spectra and structural fragments of: A. 11,12-Dehydro α-CPA (Compound 335); B: 3-Hydroxy-2-oxoCPA
(compound 369), Table S1: List of A. flavus strains used in this study, Table S2: Characteristic fragments of oxindole
CPA-type alkaloids.
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